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Numerous studies on experimental ischemic stroke use the filament middle cerebral
artery occlusion (fMCAo) model in C57BL/6 mice, but lesion sizes in this strain are highly
variable. A known contributor is variation in the posterior communicating artery (PcomA)
patency. We therefore aimed to provide a semiquantitative non-invasive in vivo method
to routinely assess PcomA patency. We included 43 male C57BL/6 mice from four
independent studies using a transient 45 min fMCAo model. Edema-corrected lesion
sizes were measured by magnetic resonance (MR) imaging 24 h after reperfusion. Time-
of-flight MR angiography was performed 7 days before and 24 h after fMCAo. Scores of
PcomA size measured 24 h after, but not scores measured 7 days before fMCAo were
negatively correlated with lesion size. Variability in PcomA patency explained 30% of the
variance in our cohort (p < 0.0001, coefficient of determination r2 = 0.3). In a simulation
using parameters typical for experimental stroke research, the power to detect a true
effect of d = 1 between two groups increased by 15% when an according covariate
was included in the statistical model. We have demonstrated that in vivo measurement
of PcomA size is feasible and can lead to increased accuracy in assessing the effect
of treatments.
Keywords: stroke, mouse, angiography, MRI, posterior communicating artery, lesion size
INTRODUCTION
Animal models of focal cerebral ischemia are a cornerstone of stroke research, as indicated by
over 1.000 experimental treatments for acute stroke that have been evaluated in these models
(O’Collins et al., 2006). A prerequisite for a successful translation of preclinical findings into clinical
trial is selection of the correct target in preclinical experiments (Dirnagl and Macleod, 2009; Sena
et al., 2010). Possibly the greatest risk to reproducibility of results and correct target selection
comes from the omnipresence of small sample sizes and correspondingly low statistical power
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(Button et al., 2013). Low statistical power can lead to
overestimation of effect sizes and low positive predictive value
of positive findings but also increases the risk of overlooking the
true effects of therapeutics at an early stage (Button et al., 2013;
Munafò et al., 2014). Here, we propose a method to increase
power and reduce noise in one of the most widely used stroke
models and one of the most common animal strains.
The intraluminal filament method of middle cerebral artery
occlusion (fMCAo) is among the most commonly used methods
to induce focal ischemic stroke in animal studies (Morris
et al., 2016). In order to reduce the imbalance of covariates in
preclinical stroke models, standard operating procedures and
refinements to the methods have been formulated to control
known determinants of outcome variables (Connolly et al.,
1996; Dirnagl, 2012; Morris et al., 2016). Often, the variance in
lesion size, which is one of the main outcome parameters, is as
high as 40% of the mean, rendering the generation of robust
and reproducible data with prevalently used small sample sizes
difficult (Dirnagl, 2006). The extent of this variability greatly
depends on the mouse strain used in the experiment (Yang
et al., 1997; Kitagawa et al., 1998). One of the most commonly
used mouse strains, but at the same time one of the strains
with the largest variability in lesion size, is C57BL/6, due to
its widespread use for generating genetically modified mice
(Kitagawa et al., 1998; Maeda et al., 1998; McColl et al., 2004).
One of the factors determining the variability in lesion size
is the patency of the circle of Willis in this strain (Kitagawa
et al., 1998; Maeda et al., 1998; McColl et al., 2004). Blood
supply to the rodent brain is provided through four main
arteries: two vertebral arteries posteriorly and two carotid arteries
anteriorly. At the base of the brain, these arteries are connected
by anastomoses, forming the circle of Willis, with two posterior
communicating arteries and one anterior communicating artery.
In 1998, Kitagawa showed that the patency of the posterior
communicating artery (PcomA) is a crucial determinant of the
lesion size in the fMCAo model (Kitagawa et al., 1998). Of
note, nomenclature for the communicating arteries in mice is
inconsistent in the literature. In this paper, we adhered to the
nomenclature used in the work published by Kitagawa et al.
(1998) describing the connecting artery between the superior
cerebellar artery (SCA) and the posterior cerebral artery (PCA)
as PcomA, which corresponds to the P1 segment of the human
PCA (Xiong et al., 2017).
In this study, we sought to establish an in vivo imaging
approach to assess the patency and size of the PcomA as a
determinant of lesion size, to be used in adjusting for pre-existing
differences in this important covariate. Including this variable in
the statistical model to test for treatment effects in preclinical
stroke models might increase power and precision to detect true
effects and arrive at more precise estimates of effect sizes.
MATERIALS AND METHODS
Animals and Experimental Groups
All experimental procedures were approved by the “Landesamt
für Gesundheit und Soziales Berlin” under registration numbers
G0005/16, G0065/17 and G0261/17 and were in accordance
with national and institutional guidelines for the care and use
of laboratory animals and with directive 2010/63/EU of the
European Parliament and of the Council of 22 September 2010.
The reporting conforms to the ARRIVE guidelines (Kilkenny
et al., 2010). A total of 33 C57BL/6J (group 1–3) and 10
C57BL/6N mice (group 4) (10 weeks old, mean weight 25 ± 2 g)
were used from control groups of four studies testing different
neuroprotective treatments. C57BL/6J and C57BL/6N mice were
purchased from Charles River Germany, and the animals were
housed in groups of 3–5 per cage with a standard light-dark cycle
(12 h:12 h) and ad libitum access to food and water. Animals
were rested for 7 days upon arrival to the laboratory. Investigating
the association between PcomA patency and lesion size was pre-
specified as an independent study goal in the study protocols. The
animals included in the analysis for the present study were either
naïve or treated with a vehicle depending on the respective group
(non-reactive mGo53 Antibodies (Wardemann et al., 2003) for
group 1 and 3, phosphate buffered saline for group 2 and no
treatment for group 4. Group 1 (n = 10) was used to establish the
method for MRA acquisition and semiquantitative measurement
of PcomA size 24 h after fMCAo described below. Five animals
in group 1 were used to study PcomA size ex vivo by Evans Blue
perfusion after MRA acquisition. Group 2 and group 3 (group
2: n = 13; group 3: n = 10) underwent the same protocol of
45 min fMCAo followed by magnetic resonance imaging (MRI)
and magnetic resonance angiography (MRA) 24 h after fMCAo.
The sample size for group 2 was calculated assuming an effect
size of r2 = 0.6 at an α = 0.05 and a power level of 0.8 based on
results from group 1.
To test the robustness of the method, we included an
additional group from another experimental hardware setup
(group 4: n = 10). The protocols for 45 min fMCAo were the
same in group 4 as in the other groups. The fMCAo surgery
and MRI / MRA acquisition were performed by two independent
researchers. Groups 2 and 4 underwent additional baseline MRA
scans 7 days before fMCAo. Figure 1 gives an overview of the
experiments included in this study.
Randomization, Blinding, and Exclusion
Criteria
For randomization, animals were numbered, and operation
order was randomly assigned. For all protocols and outcome
assessments, the experimenters were blinded. All outcome
assessments were performed by observers blinded to previous
treatments and outcomes. All animals included in the study (n
= 43) were included in the analyses.
Model of Middle Cerebral Artery
Occlusion in Mice
All experimental procedures were conducted by a trained
experimenter following published standard operating procedures
(Dirnagl, 2012). A transient fMCAo model was generated as
described previously (Engel et al., 2011). Mice were anesthetized
using 2.5% (vol/vol) isoflurane for induction and 1.5% (vol/vol)
isoflurane for maintenance, mixed in both cases with 30% O2 and
∼68% N2O. After permanent occlusion of the ipsilateral external
carotid and the common carotid artery, cerebral ischemia was
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FIGURE 1 | Experiments performed per experimental group.
induced by introducing a 7-0 silicon-rubber-coated fMCAo
suture with a coating length of 9–10 mm (monofilament
7019910PK5Re, Doccol Corp., Sharon MA, United States) into
the left internal carotid artery and advancing it up to the anterior
cerebral artery, thereby occluding the middle cerebral artery.
The filament was withdrawn after an occlusion time of 45 min.
Rectal temperature was maintained at 37.5 ± 0.5◦C throughout
the experiment using a feedback-controlled heating pad with a
rectal probe (Fine Science Tools GmbH, Heidelberg, Germany).
During fMCAo and for at least 2 h after reperfusion, animals
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were allowed to recover in a heated cage (Peco Services, Cumbria,
United Kingdom). Afterward, they were transferred to the home
cage. After fMCAo, animals had access to soft food and were
treated with subcutaneous saline injections to ensure adequate
hydration after surgery.
Evans Blue Perfusion
For Evans Blue perfusion and vessel fixation, mice were deeply
anaesthetized with ketamine and xylazine at the conclusion of
the experiment and perfused through the heart with physiological
saline followed by 4% paraformaldehyde, Termofisher, W32465,
3% Gelatin (Sigma-Aldrich, G1890), 1% low melting agarose
(Sigma Aldrich A4018) and 0.1% Evans Blue (Sigma Aldrich
E2129) as described previously (Foddis et al., 2019).
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) was conducted on a 7-Tesla
rodent scanner running Paravision 5.1 software (Pharmascan
70/16, Bruker, Ettlingen, Germany) with a 16 cm horizontal
bore magnet and a 9 cm (inner diameter) shielded gradient
with a maximum gradient strength of 300 mT/m. Mice were
anesthetized under 1.5% isoflurane in a mixture of 30% O2/68.5%
N2O and scanned under constant respiration monitoring (Small
Animal Monitoring & Gating System, SA Instruments, Stony
Brook, New York, United States). Animals were placed prone
and head fixed on a heated circulating water blanket to ensure
a constant body temperature of 37 ± 0.5◦C.
For groups 1–3, a 72 mm volume resonator (RAPID
Biomedical, Rimpar, Germany) was used for transmission, and
an actively decoupled mouse head surface coil was used for
signal reception. After coil tuning and matching, scout images
were acquired. Similar geometry of all scans across animals
was assured by using the anterior commissure as a landmark
in rostral-caudal direction and the trachea as a landmark in
the other directions. T2-weighted images were acquired using
a 2D turbo spin-echo sequence (2D RARE) with repetition
time (TR) = 4200 ms, echo time (TE) = 36 ms, echo spacing
(1TE) = 12 ms, RARE factor = 8, 4 averages, 32 contiguous
axial slices with a slice thickness of 0.5 mm, field of view
(FOV) = 25.6 × 25.6 mm2, matrix size MTX = 256 × 256,
bandwidth BW = 46875 Hz, and total acquisition time TA = 6 min
43 s). Angiography with matching geometry but higher resolution
was performed with a non-flow compensated 3D-FLASH time-
of-flight (TOF) sequence with TR/TE = 15 ms/2.5 ms, 1 ms
sinc-shaped excitation pulse with 22 kHz bandwidth and
flip angle FA = 20◦, FOV = 25.6 × 25.6 × 16.0 mm3,
MTX = 256 × 223 × 139 zero filled to 256 × 256 × 160,
BW = 98684 Hz, TA = 7 min 50 s.
For group 4, a transmit/receive quadrature volume resonator
with an inner diameter of 20 mm (RAPID) was used. T2-
weighted images were acquired with the same sequence as groups
1–3. Angiography with FOV centered to the FOV of the T2-
weighted sequence was acquired with a 3D-FLASH TOF using
identical settings as for groups 1–3 but TR/TE = 14 ms/2.3 ms,
FOV = 19.2 × 19.2 × 16.0 mm3, MTX = 192 × 167 × 139 zero
filled to 192 × 192 × 160, TA = 5 min 29 s.
Atlas Registration
T2-weighted images were registered to the Allen Brain Atlas1 as
described previously (Koch et al., 2017) using ANTX2, a custom
MATLAB toolbox comprising a segmentation in SPMMouse3
followed by non-linear warping of tissue probability maps in
ELASTIX4. The calculated image transformation could then be
applied to other images aligned with the T2-weighted scan,
including TOF angiograms and lesion masks.
Corrected Lesion Volume
Lesion volume corrected for brain swelling was calculated
as described previously (Koch et al., 2017). Briefly, ischemic
tissue appearing hyperintense on T2-weighted images 24 h after
stroke was manually delineated by an experienced researcher,
carefully omitting ventricles, using ANALYZE 5.0 software
(AnalyzeDirect, Overland Park, KS, United States), and masks of
the same dimensionality as the T2-weighted image were exported
in NIFTI format. Using nearest neighbor interpolation, lesion
masks were registered to the Allen Brain Atlas. Edema-corrected
lesion volume in percent was defined as the volume of the lesion
divided by volume of the hemisphere measured in atlas space.
Semiquantitative Assessment of PcomA
Patency
ImageJ distribution 1.51m9 (Schneider et al., 2012) was used
for post-processing atlas-registered angiograms to obtain scores
for PcomA patency and size. Atlas registration allowed us to
determine a set of 10 slices that contained the posterior part
of the circle of Willis in all animals. To render pixel intensity
comparable between individual datasets, we then calculated the
signal-to-noise ratio (SNR) of each dataset adjusted as described
previously (Gudbjartsson and Patz, 1995; Boehm-Sturm et al.,
2011) and set a threshold to 1/10 of the maximum intensity
of the dataset, setting all other values to NaN. In the next
step, the area between the superior cerebellar artery (SCA) and
posterior cerebral artery (PCA) was manually delineated on
all selected slices. The maximum SNR in this area depends
on background intensity and on the flow signal present, with
higher intensities for higher flow. The only larger vessel in
this anatomical area is the PcomA (Xiong et al., 2017). We
therefore used the maximum SNR measured over the stack of
slices as a correlate and semiquantitative score of the flow and
thus the patency of the PcomA. Only the side ipsilateral to
the ischemic lesion was assessed. ImageJ code is available on
www.figshare.com at https://www.doi.org/10.6084/m9.figshare.
8950328.
Validation by Manual in vivo and ex vivo
Assessments of PcomA
The semiquantitative assessment of PcomA patency was
correlated to an in vivo score of PcomA size in the described
1http://portal.brain-map.org/
2Latest version available under https://github.com/ChariteExpMri/antx2
3http://www.spmmouse.org/
4http://elastix.isi.uu.nl/
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target region assessed and rated from 0 (meaning no vessel) to
3 (large vessel) using the same postprocessing as described above.
To quantitatively validate in vivo assessment of PcomA size,
a subset of animals was perfused with Evans Blue and ex vivo
photographs of excised brains were taken. PcomA size was
measured in percent of the basilar artery in vivo on maximum
intensity projections of raw TOF images and ex vivo on Evans
Blue labeled vasculature.
Simulation
A statistical program was developed in STATA 13.0 (StataCorp,
College Station, United States) to simulate a hypothetical two-
arm trial testing the effect of a hypothetical treatment. The
simulation code was based on work by Egbewale et al. (2014)
describing the method to simulate data for clinical trials. Based
on assumptions common in preclinical stroke research (Howells
et al., 2012), we set the standardized effect size at d = 1.0.
Setting the α error probability at 0.05 and the power at 0.8,
we set the sample size at n = 14 per group. A normally
distributed covariate with varying degrees of correlation with
the outcome variable was introduced. Five different experimental
conditions with correlation coefficients between the covariate
and the outcome variable of r2 = 0, 0.01, 0.04, 0.09, 0.16, 0.25,
0.29, 0.36, 0.49, and 0.64 were simulated. Outcome analysis
was performed by either ANOVA or ANCOVA adjusting for
the covariate in each individual experiment. Each hypothetical
scenario and outcome analysis combination was repeated 1000
times to obtain reliable estimates of actual power. STATA code is
available on www.figshare.com at https://www.doi.org/10.6084/
m9.figshare.9752834.
Statistical Evaluation
Data are represented as the Pearson correlation coefficient r or
as the coefficient of determination r2 and calculated probability
value (p-value) using the general linear model. For testing
of manual ratings measured on an ordinal scale, data are
represented as Spearman rank-order correlation coefficient rS.
Data Availability
Source code for the simulation in STATA and the code for
the macro used to postprocess images for semiquantitative
measurement in ImageJ are available in the Appendix. All
relevant original and Allen Brain Atlas-registered images
are publicly available at http://doi.org/10.6084/m9.figshare.
9752864.
RESULTS
TOF MRA Can Image PcomA Size After
fMCAo
PcomA size was assessed ex vivo 7 days after fMCAo in five
animals of group 1 (Figure 2). Ex vivo PcomA vessel size was
measured after Evans Blue perfusion in relation to the size of
the basilar artery and compared to corresponding measurements
obtained in vivo 24 h after fMCAo by MR angiography. PcomA
size measured by MRA was highly correlated (n = 5, r2 = 0.81)
with ex vivo PcomA size measurements, yet statistical significance
was not reached (p = 0.057).
Semiquantitative Measurement of
PcomA Patency by MRA Is Correlated
With Manual PcomA Size Ratings
To validate the semiquantitative measurement of PcomA patency
with an independent data analysis method, we compared
semiquantitative measurements to independently conducted
manual ratings (Figure 3). All imaging studies followed the same
procedure of atlas registration before being further processed
for unbiased semiquantitative measurement. The same atlas-
registered datasets were used for evaluation by three trained
raters blinded to the total lesion volume. Raters were trained with
a standard set from group 1. There was a good correlation of
manually rated PcomA size and semiquantitative measurement
of PcomA patency (Spearman rank-order correlation coefficient
FIGURE 2 | TOF MRA images and corresponding images of vasculature after Evans Blue perfusion. TOF-MR angiography 24 h after fMCAo readily images the circle
of Willis and PcomA (A–E). Evans Blue perfusion 7 days after fMCAo clearly depicts the corresponding vasculature (F–J). Yellow boxes highlight the PcomA
ipsilateral to the ischemic lesion. Individual data points of images (A–J), respectively, comparing readings of PcomA diameter as percentage of basilar artery
diameter from MRA and from images after Evans Blue perfusion (K). PCA – posterior cerebral artery, PcomA – posterior communicating artery, SCA – superior
cerebellar artery.
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FIGURE 3 | Semiquantitative measurement of PcomA size and manual PcomA assessment. Whole brain TOF MRA recordings (A) were normalized to the Allen
Brain atlas (B) to define a set of slices that contain the location of the PcomA in all animals. Semiquantitative measurements of PcomA patency were taken by
assessing the maximum SNR in a manually delineated region of interest between the SCA and the PCA (C) in these slices. Examples of Allen atlas-normalized
maximum intensity projections with large (D), medium (E), small (F) and absent (G) PcomA used for the training of raters to manually rate PcomA size. Examples of
T2 MRI images used to obtain a mask of the ischemic lesion (H).
rS = 0.7, p < 0.0001). Ratings for the size of the PcomA on each
side varied between independent raters, but interrater reliability
was high (interclass correlation = 0.9, p < 0.001).
Semiquantitative Measurement of
PcomA Patency Partially Explains
Variability in Lesion Size
Unbiased semiquantitative measurement of PcomA patency from
TOF angiograms recorded at 24 h after fMCAo significantly
negatively correlated with lesion size determined by T2 weighted
MRI at 24 h (Figure 4) in 4 independent datasets. In the first
training set, 62% of intersubject variability of total lesion size
was explained by PcomA patency (r2 = 0.62) alone. Applying
this algorithm to three independent datasets, 16–49% (r2 = 0.16–
0.49) (Table 1) of variability in lesion size in these individual
groups was explained by differences in semiquantitative PcomA
patency measurements. Pooling data from all groups resulted in
a highly significant correlation explaining 34% of the variance in
the dataset, r2 = 0.34, p < 0.0001 (Figure 5).
Semiquantitative Measurement of
PcomA Patency Prior to fMCAo Cannot
Reliably Predict Infarct Size
There was a moderate correlation between mean manual
PcomA size ratings before fMCAo and unbiased semiquantitative
measurement of PcomA patency 24 h after fMCAo (r = 0.63,
r2 = 0.40, p = 0.001). While there was still a trend for a
moderate correlation between mean manual PcomA size ratings
before fMCAo and MRI lesion size 24 h after fMCAo (Spearman
rank-order correlation coefficient r = −0.40, p = 0.051),
semiquantitative PcomA measurement before fMCAo did not
reliably predict lesion size across 2 datasets (group 2 and group
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FIGURE 4 | Correlation of PcomA score and lesion size 24 h after fMCAo. Lesion sizes of each animal included in this study and corresponding semiquantitative
scores of PcomA patency (A). A method to obtain PcomA scores was developed using group 1 (B). The results were replicated in three additional independent
groups 2–4 (C–E).
4; r = −0.0186, r2 = 0.0003, p = 0.933). For group 1 and group 3,
no baseline MRA before fMCAo was recorded.
Including PcomA Size as a Covariate
Increases Power in a Simulation
Preclinical Stroke Study
We conducted a simulation experiment to test whether the power
of the final outcome analysis increases by including a covariate
with the magnitude of correlation found for the association
between PcomA patency and lesion size in this study. In this
simulation, the power to detect an effect with a standardized effect
size of d = 1 increased by 12% when adjusting for a covariate
with a correlation coefficient of r2 = 0.25 and further increased
for stronger associations between the covariate and the outcome
variable (Figure 5).
Distribution of PcomA Phenotypes in
C57BL/6 Mice and Correlation With
Lesion Size
The vascular anatomy was examined using TOF MRA images
recorded 24 h after fMCAo and separate manual ratings of
whether the PcomA was patent on each side. In our cohort, we
found a complete circle of Willis in 21% (9/43), a patent PcomA
on one side in 53% (23/43) and a bilateral lack of patent PcomAs
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TABLE 1 | Correlation of semiquantitative scores of PcomA patency and lesion






Group 1 10 −0.76 0.62 <0.01
Group 2 13 −0.4 0.16 0.09
Group 3 10 −0.61 0.38 0.05
Group 4 10 −0.7 0.49 0.023
All Groups 43 −0.58 0.34 <0.0001
in 26% (11/43) of animals. Ischemic lesion size was significantly
correlated with PcomA phenotype, with smaller lesion sizes in
animals with a complete circle of Willis (r2 = 0.32, p = 0.0001).
DISCUSSION
We developed an easy-to-implement semiquantitative method to
assess PcomA patency in vivo using readily available standard
mouse MRI sequences. We demonstrated that the obtained
dimensionless score negatively correlates with the lesion size
after fMCAo in C57BL/6 mice. In a simulation experiment
representative of common study designs in preclinical stroke
research, we showed that by including this score as a
covariate in the model, the power to detect a true effect
increased by almost 20%.
The fMCAo model is widely used to model human focal
cerebral ischemia (Kleinschnitz et al., 2015). One of its inherent
disadvantages is the high intersubject variability of common
outcome parameters. Several variables have been shown to impact
lesion volume, one of the most important outcome parameters
(Morris et al., 2016); including different parameters of the model
itself, such as the occlusion and recovery time (Harada et al., 2005;
Liu et al., 2009), the filament and anesthetic used (Michenfelder
et al., 1976; Tsuchiya et al., 2003), differences in the surgical
technique (Chen et al., 2008) as well as parameters of the animals,
such as the species (Carmichael, 2005), strain (Yang et al., 1997;
Kitagawa et al., 1998), substrain (Zhao et al., 2019), sex (Alkayed
et al., 1998; Zhao et al., 2019), age (Sutherland et al., 1996), and
interindividual variation in cerebrovascular anatomy (Barone
et al., 1993; Kitagawa et al., 1998; McColl et al., 2004). Species
and strain differences in the cerebrovascular architecture and
in particular differences in the patency of macroanastomoses
formed in the circle of Willis have already been studied previously
(Barone et al., 1993; Kitagawa et al., 1998; McColl et al., 2004). In
a study in 1998, Kitagawa and colleagues demonstrated species
and strain differences of the circle of Willis in mice (Kitagawa
et al., 1998; Ankolekar et al., 2012). In the same study, they
were able to establish patency of the PcomA as a determinant
of parenchymal ATP drop in a model of bilateral carotid artery
occlusion and mortality and lesion size in fMCAo. To predict the
vascular anatomy, they proposed a method using laser Doppler
flow measurement of cerebral microvascular perfusion and a
one-minute bilateral common carotid artery (CCA) occlusion.
However, this method could neither determine whether the
PcomA was patent on one or both sides nor detect the side of
a unilaterally patent PcomA. The authors concluded that PcomA
FIGURE 5 | Power to detect an effect of d = 1 with and without adjusting for a covariate. Adjusting for a single covariate in the outcome analysis (ANCOVA)
increased the power to detect a true effect by up to 25% compared to no adjustment (ANOVA) depending on the magnitude of the correlation coefficient of covariate
and outcome variable. Effect size d = 1, n = 14 per group, 1000 repetitions per condition. Coefficient of determination found in this study for the association of
PcomA score and lesion size marked in yellow (r2 = 0.34).
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patency should be assessed for every animal in models of cerebral
ischemia, but that their own method could be used only to predict
forebrain ischemia after bilateral CCA occlusion and not for
unilateral MCAo. Additional evidence of the impact of PcomA
patency and the variability of PcomA patency in C57BL/6J mice
comes from McColl and colleagues: in a small sample of 10
C57BL/6J mice, they found a complete circle of Willis in only
1 animal. In 6 animals, the PcomA was patent only unilaterally,
and in another 3 animals, no patent PcomA was found (McColl
et al., 2004). In our own cohort of 43 animals, we found a
slightly different distribution: we confirmed that a plurality of
animals had a single patent PcomA, while almost equal numbers
of animals had bilaterally patent PcomAs and complete absence
of the posterior part of the circle of Willis. The notion of PcomA
patency being one of the main determinants of mortality and
lesion size in the fMCAo model is corroborated by a recent
exploratory study by Foddis et al. (2019) reporting an almost
equal distribution among different PcomA phenotypes (no patent
PcomA, unilateral patent PcomA or bilateral patent PcomAs).
While the distribution of patent PcomA in C57BL/6 mice in that
study differs from the report by McColl and colleagues and our
own findings, it still confirms the general conclusion of a high
degree of variability in C57BL/6 mice.
Randomization is a cornerstone of all trials of treatment
effects. Randomization seeks to prevent bias in the allocation
of subjects to treatment groups and is the prerequisite of any
statistical testing. To ensure balanced distribution of all known
and unknown covariates influencing the dependent variable(s), is
the primary goal of randomization. Imbalance in covariates that
strongly correlate and determine the outcome variable can lead
to an overestimation of the treatment effect or to false negative
results, depending on the direction of correlation and the level of
imbalance. For clinical trials, methods to adjust for imbalances
of known covariates both at the design stage (i.e., stratification)
as well as at the stage of data analysis (i.e., by including the
covariates in the statistical model) have been commonly adopted
(Schneider et al., 2012). The risk of imbalance grows with
increasing levels of variability of a given variable in the statistical
population and with decreasing sample size. Smaller sample sizes
are also associated with an increasing effect of any imbalance
in covariates on precision, effect size and power (Button et al.,
2013). In preclinical biomedical research, sample sizes are often
under 10 animals per group (Button et al., 2013), increasing
the impact of imbalance of covariates, especially those (such as
PcomA patency) that are strongly correlated with the outcome
parameter. We therefore argue that adjustments for imbalances
in the distribution of animals with different PcomA statuses could
be beneficial for all stroke studies using C57BL/6 mice.
In recent years, high-resolution mouse MRI has become
widely available at almost all large stroke research centers.
Beckmann and colleagues have demonstrated that high-
resolution MRA can be used to non-invasively image
cerebrovascular anatomy, including large collaterals in the
circle of Willis in mice (Beckmann et al., 1999; Beckmann,
2000). Building on this work, we and others have refined MRA
protocols to obtain high-resolution MRA in less than 10 min
per animal, rendering the technique applicable for routine use
in preclinical stroke research when MRI is included in the
study design. Beckman and colleagues proposed using this
method for selecting or stratifying animals according to the
PcomA status. However, our current data on the inconsistent
association of PcomA patency evaluated before fMCAo and the
ischemic lesion size, as well as data reported in a recent study
by Foddis and colleagues, highlight challenges of this approach
(Foddis et al., 2019).
There are several possible explanations for the failure to
predict lesion size from pre-fMCAo PcomA evaluation. It is
possible that the resolution currently available in TOF MRA
sequences is not sufficient to distinguish between smaller PcomA
vessel diameters in preischemic conditions. This notion is
support by our finding of a moderate, yet statistically not
significant (p = 0.051), correlation of manual PcomA size ratings
before fMCAo and infarct size 24 h after fMCAo, a signal not
picked up by our semiquantitative score for PcomA patency.
Studies using contrast-enhanced MRA with a cryogenically
cooled MR coil and extended recording time demonstrated
the technical possibility of imaging vessels with diameters of
down to 40 µm (Klohs et al., 2012). Further studies using
this technique would be needed to validate this hypothesis.
Contrast-enhanced MRA, however, requires long sequences and
is inherently invasive, rendering this method less suitable for
routine use. In line with the findings reported in this study,
Foddis and colleagues found PcomA to be small and not
reliably identifiable on MRA in naïve conditions, while under
postischemic conditions PcomA is recruited and reaches a vessel
size of up to 60% of the basilar artery diameter (Foddis et al.,
2019). Despite our finding of a moderate correlation of manual
PcomA scores pre-fMCAo and semiquantitative PcomA scores
after fMCAo, this might indicate that preischemic PcomA size
is only one of several determinants of PcomA perfusion under
ischemic conditions. Interindividual differences in collateral
recruitment under hypoperfusion might also play a role. In fact,
our finding of no reliable prediction of lesion size by preischemic
PcomA scores suggests that not the preischemic anatomical
size of the PcomA but the postischemic flow after collateral
recruitment is what determines ischemic lesion size. Collateral
status has recently been shown to be a key predictor of lesion size
evolution in the first 24 h in humans (Rao et al., 2020). It can
thus be hypothesized that postischemic PcomA flow as measured
in this study is only a correlate of a general level of collateral
recruitment in the individual animal determining the size of
the ischemic lesion. In this scenario, interindividual differences
concerning collateral recruitment might be more important for
lesion development than the initial PcomA vessel size pre fMCAo.
We therefore argue that using a measurement of the postischemic
PcomA status by TOF MRA obtained 24 h after fMCAo as
a covariate in the outcome analysis is most relevant to adjust
for imbalances in interindividual differences of cerebrovascular
anatomy and function.
The inaptitude to measure PcomA patency as a determinant of
ischemic lesion size in naïve, pre-fMCAo condition is at the same
time one to the strongest limitations of the proposed approach.
In the case of a treatment paradigm with early treatment within
the first 24 h or pre-fMCAo treatment paradigms, the interaction
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of the treatment and the PcomA size cannot be excluded. This
is particularly problematic for treatments targeting collateral
recruitment. In these cases, adjusting for PcomA patency bears
the risk of reducing power to detect the treatment effect and
cannot be recommended. For experimental paradigms with
postischemic treatment randomization later than 24 h after
fMCAo, the proposed approach would allow for combining
stratified randomization for PcomA status and including PcomA
status as a covariate using ANCOVA to control for imbalances of
this important covariate. In our study, we focused on variability
in acute lesion size as one of the most widely used outcome
parameters in experimental ischemic stroke studies and did
not include long-term behavioral outcomes. Impact of PcomA
patency on long-term behavioral outcomes should be assessed in
future studies to test robustness of the proposed approach. To
further improve robustness of the described approach and reduce
potential bias, we aim to eliminate the currently still required
manual input in delineation of the target area and automatise
area selection for future studies. A general limitation of the
method used, is the indirect measurement of cerebral blood flow
(CBF) by morphological TOF MRA imaging. To better assess
functional patency and blood flow and relate it to morphological
PcomA status, additional measurement of CBF by non-invasive
aterial spin labeling (ASL) would be desirable. The scope of the
presented work was to use highly standardized widely available
sequences easily applicable to routine protocols. We thus did not
implement ASL in the current study protocol.
In conclusion, we have shown that including a
semiquantitative score of PcomA patency obtained 24 h after
fMCAO in the statistical model can explain a large share of
previously unexplained intersubject variability in lesion size and
thus increase the power to detect treatment effects in preclinical
stroke studies. The methods used are easy to implement for study
designs with MR imaging. Based on the findings in this study,
we therefore suggest to, (i) record an TOF MRA 24 h after
fMCAo followed by semiquantitative PcomA measurement in
any protocol evaluating experimental stroke therapies in the
subacure phase after stroke, (ii) include the semiquantitative
score of PcomA patency in the statistical model for outcome
assessment. We believe that, mirroring standard procedures in
clinical trials for which adjustment for known covariates has
become state-of-the-art, similar practices should be adopted for
preclinical trials to improve efficiency in therapy selection for
clinical translation.
DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online
repositories. The names of the repository/repositories and




The animal study was reviewed and approved by the Landesamt
für Gesundheit und Soziales Berlin.
AUTHOR CONTRIBUTIONS
SK, CA, UD, SM, CH, CJH, SPK, ME, and PB-S contributed
to designing and planning the experiments as well as obtaining
official licenses to conduct this study. SK performed the fMCAo
surgeries and blinded outcome analyses. CA, SM, and CJH
acquired the MRA and MRI datasets. SK, PB-S, and SPK
contributed in image normalization and atlas registration. ME,
CH, SK, and UD contributed in covariate analysis and simulation
design. All authors contributed in drafting and revising the
manuscript and approved the manuscript for publication.
FUNDING
Funding was provided by the German Federal Ministry of
Education and Research under the ERA-NET NEURON scheme
(BMBF 01EW1811), the German Research Foundation (DFG
research grant BO 4484/2-1 and EXC NeuroCure) and Fondation
Leducq Transatlantic Network of Excellence 15CVD02.
ACKNOWLEDGMENTS
We thank David Schreiber for helping with the logistics of the
MRI measurements and Janet Lips for support with animal
logistics and handling.
REFERENCES
Alkayed, N. J., Harukuni, I., Kimes, A. S., London, E. D., Traystman, R. J., Hurn,
P. D., et al. (1998). Gender-linked brain injury in experimental stroke. Stroke
29, 159–166. doi: 10.1161/01.str.29.1.159
Ankolekar, S., Rewell, S., Howells, D. W., and Bath, P. M. W. (2012). The influence
of stroke risk factors and comorbidities on assessment of stroke therapies in
humans and animals. Int. J. Stroke 7, 386–397. doi: 10.1111/j.1747-4949.2012.
00802.x
Barone, F. C., Knudsen, D. J., Nelson, A. H., Feuerstein, G. Z., and Willette,
R. N. (1993). Mouse strain differences in susceptibility to cerebral ischemia are
related to cerebral vascular anatomy. J. Cereb. Blood Flow Metab. 13, 683–692.
doi: 10.1038/jcbfm.1993.87
Beckmann, N. (2000). High resolution magnetic resonance angiography non-
invasively reveals mouse strain differences in the cerebrovascular anatomy
in vivo. Magnet. Reson. Med. 44, 252–258. doi: 10.1002/1522-2594(200008)44:
2<252::aid-mrm12>3.0.co;2-g
Beckmann, N., Stirnimann, R., and Bochelen, D. (1999). High-resolution magnetic
resonance angiography of the mouse brain: application to murine focal
cerebral ischemia models. J. Magn. Reson. 140, 442–450. doi: 10.1006/jmre.1999.
1864
Boehm-Sturm, P., Mengler, L., Wecker, S., Hoehn, M., and Kallur, T. (2011). In vivo
tracking of human neural stem cells with 19F magnetic resonance imaging.
PLoS One 6:e29040. doi: 10.1371/journal.pone.0029040
Button, K. S., Ioannidis, J. P. A., Mokrysz, C., Nosek, B. A., Flint, J., Robinson,
E. S. J., et al. (2013). Power failure: why small sample size undermines the
Frontiers in Neuroscience | www.frontiersin.org 10 September 2020 | Volume 14 | Article 576741
fnins-14-576741 September 18, 2020 Time: 22:49 # 11
Knauss et al. PcomA Variance in Brain Ischemia
reliability of neuroscience. Nat. Rev. Neurosci. 14, 365–376. doi: 10.1038/
nrn3475
Carmichael, S. T. (2005). Rodent models of focal stroke: size, mechanism, and
purpose. Neurorx 2, 396–409. doi: 10.1602/neurorx.2.3.396
Chen, Y., Ito, A., Takai, K., and Saito, N. (2008). Blocking pterygopalatine
arterial blood flow decreases infarct volume variability in a mouse model of
intraluminal suture middle cerebral artery occlusion. J. Neurosci. Meth. 174,
18–24. doi: 10.1016/j.jneumeth.2008.06.021
Connolly, E. S. Jr., Winfree, C. J., Stern, D. M., Solomon, R. A., and Pinsky, D. J.
(1996). Procedural and strain-related variables significantly affect outcome in
a murine model of focal cerebral ischemia. Neurosurgery 38, 523–532. doi:
10.1227/00006123-199603000-00021
Dirnagl, U. (2006). Bench to bedside: the quest for quality in experimental stroke
research. J. Cereb. Blood Flow Metab. 26, 1465–1478. doi: 10.1038/sj.jcbfm.
9600298
Dirnagl, U. (2012). Standard operating procedures (SOP) in experimental stroke
research: SOP for middle cerebral artery occlusion in the mouse. Nat. Précéd.
doi: 10.1038/npre.2012.3492.3
Dirnagl, U., and Macleod, M. R. (2009). Stroke research at a road block: the
streets from adversity should be paved with meta-analysis and good laboratory
practice. Br. J. Pharmacol. 157, 1154–1156. doi: 10.1111/j.1476-5381.2009.
00211.x
Egbewale, B. E., Lewis, M., and Sim, J. (2014). Bias, precision and statistical power
of analysis of covariance in the analysis of randomized trials with baseline
imbalance: a simulation study. BMC Med. Res. Methodol. 14:49. doi: 10.1186/
1471-2288-14-49
Engel, O., Kolodziej, S., Dirnagl, U., and Prinz, V. (2011). Modeling stroke in mice
- middle cerebral artery occlusion with the filament model. J. Vis. Exp. Jove.
2011:2423. doi: 10.3791/2423
Foddis, M., Winek, K., Bentele, K., Mueller, S., Blumenau, S., Reichhart, N., et al.
(2019). An exploratory investigation of brain collateral circulation plasticity
after cerebral ischemia in two experimental C57BL/6 mouse models. J. Cereb.
Blood Flow Meta. 40, 276–287. doi: 10.1177/0271678x19827251
Gudbjartsson, H., and Patz, S. (1995). The rician distribution of noisy mri data.
Magnet. Reson. Med. 34, 910–914. doi: 10.1002/mrm.1910340618
Harada, H., Wang, Y., Mishima, Y., Uehara, N., Makaya, T., and Kano, T. (2005). A
novel method of detecting rCBF with laser-Doppler flowmetry without cranial
window through the skull for a MCAO rat model. Brain Res. Protoc. 14,
165–170. doi: 10.1016/j.brainresprot.2004.12.007
Howells, D. W., Sena, E. S., O’Collins, V., and Macleod, M. R. (2012). Improving
the efficiency of the development of drugs for stroke. Int. J. Stroke 7, 371–377.
doi: 10.1111/j.1747-4949.2012.00805.x
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., and Altman, D. G. (2010).
Improving bioscience research reporting: the ARRIVE guidelines for reporting
animal research. PLoS Biol. 8:e1000412. doi: 10.1371/journal.pbio.1000412
Kitagawa, K., Matsumoto, M., Yang, G., Mabuchi, T., Yagita, Y., Hori, M.,
et al. (1998). Cerebral ischemia after bilateral carotid artery occlusion and
intraluminal suture occlusion in mice: evaluation of the patency of the posterior
communicating artery. J. Cereb. Blood Flow Metab. 18, 570–579. doi: 10.1097/
00004647-199805000-00012
Kleinschnitz, C., Fluri, F., and Schuhmann, M. (2015). Animal models of ischemic
stroke and their application in clinical research. Drug Des. Dev. Ther. 9,
3445–3454. doi: 10.2147/dddt.s56071
Klohs, J., Baltes, C., Princz-Kranz, F., Ratering, D., Nitsch, R. M., Knuesel,
I., et al. (2012). Contrast-enhanced magnetic resonance microangiography
reveals remodeling of the cerebral microvasculature in transgenic ArcAβ Mice.
J. Neurosci. 32, 1705–1713. doi: 10.1523/jneurosci.5626-11.2012
Koch, S., Mueller, S., Foddis, M., Bienert, T., von Elverfeldt, D., Knab, F.,
et al. (2017). Atlas registration for edema-corrected MRI lesion volume in
mouse stroke models. J. Cereb. Blood Flow Metab. 39, 313–323. doi: 10.1177/
0271678x17726635
Liu, F., Schafer, D. P., and McCullough, L. D. (2009). TTC, Fluoro-Jade B and NeuN
staining confirm evolving phases of infarction induced by middle cerebral artery
occlusion. J. Neurosci. Meth. 179, 1–8. doi: 10.1016/j.jneumeth.2008.12.028
Maeda, K., Hata, R., and Hossmann, K.-A. (1998). Differences in the
cerebrovascular anatomy of C57Black/6 and SV129 mice. Neuroreport 9:1317.
doi: 10.1097/00001756-199805110-00012
McColl, B. W., Carswell, H. V., McCulloch, J., and Horsburgh, K. (2004). Extension
of cerebral hypoperfusion and ischaemic pathology beyond MCA territory
after intraluminal filament occlusion in C57Bl/6J mice. Brain Res. 997, 15–23.
doi: 10.1016/j.brainres.2003.10.028
Michenfelder, J. D., Milde, J. H., and Sundt, T. M. (1976). Cerebral protection
by barbiturate anesthesia: use after middle cerebral artery occlusion in java
monkeys. Arch. Neurol. Chicago 33, 345–350. doi: 10.1001/archneur.1976.
00500050031006
Morris, G. P., Wright, A. L., Tan, R. P., Gladbach, A., Ittner, L. M., and Vissel, B.
(2016). A Comparative study of variables influencing ischemic injury in the
longa and koizumi methods of intraluminal filament middle cerebral artery
occlusion in mice. PLoS One 11:e0148503. doi: 10.1371/journal.pone.0148503
Munafò, M., Noble, S., Browne, W. J., Brunner, D., Button, K., Ferreira, J., et al.
(2014). Scientific rigor and the art of motorcycle maintenance. Nat. Biotechnol.
32, 871–873. doi: 10.1038/nbt.3004
O’Collins, V. E., Macleod, M. R., Donnan, G. A., Horky, L. L., van der Worp, B. H.,
and Howells, D. W. (2006). 1,026 experimental treatments in acute stroke. Ann.
Neurol. 59, 467–477. doi: 10.1002/ana.20741
Rao, V. L., Mlynash, M., Christensen, S., Yennu, A., Kemp, S., Zaharchuk, G.,
et al. (2020). Collateral status contributes to differences between observed and
predicted 24-h infarct volumes in DEFUSE 3. J. Cereb. Blood Flow Metab.
40:0271678X2091881. doi: 10.1177/0271678x20918816
Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012). NIH image to imageJ:
25 years of image analysis. Nat. Methods 9:671. doi: 10.1038/nmeth.2089
Sena, E. S., van der Worp, H. B., Bath, P. M. W., Howells, D. W., and Macleod,
M. R. (2010). Publication bias in reports of animal stroke studies leads to
major overstatement of efficacy. PLoS Biol. 8:e1000344. doi: 10.1371/journal.
pbio.1000344
Sutherland, G. R., Dix, G. A., Auer, R. N., and Koehler, R. C. (1996). Effect of
age in rodent models of focal and forebrain ischemia. Stroke 27, 1663–1668.
doi: 10.1161/01.str.27.9.1663
Tsuchiya, D., Hong, S., Kayama, T., Panter, S. S., and Weinstein, P. R. (2003). Effect
of suture size and carotid clip application upon blood flow and infarct volume
after permanent and temporary middle cerebral artery occlusion in mice. Brain
Res. 970, 131–139. doi: 10.1016/s0006-8993(03)02300-x
Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E., and
Nussenzweig, M. C. (2003). Predominant autoantibody production by early
human B cell precursors. Science 301, 1374–1377. doi: 10.1126/science.1086907
Xiong, B., Li, A., Lou, Y., Chen, S., Long, B., Peng, J., et al. (2017). Precise
cerebral vascular atlas in stereotaxic coordinates of whole mouse brain. Front.
Neuroanat. 11:128. doi: 10.3389/fnana.2017.00128
Yang, G., Kitagawa, K., Matsushita, K., Mabuchi, T., Yagita, Y., Yanagihara, T.,
et al. (1997). C57BL/6 strain is most susceptible to cerebral ischemia following
bilateral common carotid occlusion among seven mouse strains: selective
neuronal death in the murine transient forebrain ischemia. Brain Res. 752,
209–218. doi: 10.1016/s0006-8993(96)01453-9
Zhao, L., Mulligan, M. K., and Nowak, T. S. (2019). Substrain- and sex-dependent
differences in stroke vulnerability in C57BL/6 mice. J. Cereb. Blood Flow Metab.
39, 426–438. doi: 10.1177/0271678x17746174
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Knauss, Albrecht, Dirnagl, Mueller, Harms, Hoffmann, Koch,
Endres and Boehm-Sturm. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 11 September 2020 | Volume 14 | Article 576741
